ALSEN Share Price Performance
€0.37
-0.09 (-19.40%)
Price €0.37
Share Pricen/a
Sensorion SA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ALSEN Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Sensorion SA Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.055
- 100.00%
- -497.26%
- 1.5%
About ALSEN
- Founded
- 2009
- Employees
- 68
- CEO
- WebsiteView website
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
